Stock
Daily Margin Trading Facility book for AARTIPHARM across NSE and BSE, from 06 Feb 2025. All figures in ₹ crore, derived from exchange public disclosures.
Funded value
₹64 Cr
as of 10 Sep 2026
Rank in book
#557
240 days tracked
Share of book
0.04%
of the whole NSE + BSE book
Peak funded
₹64 Cr
on 10 Sep 2026
Largest single-day addition
+₹14 Cr
on 11 Aug 2026
Largest single-day unwind
−₹11 Cr
on 10 Aug 2026
NSE & BSE split
How AARTIPHARM’s funded book divides across the two exchanges, as of 10 Sep 2026.
NSE ₹62 Cr · 97.8%BSE ₹1 Cr · 2.2%
MTF vs Price
Margin-funded outstanding for AARTIPHARM in ₹ crore
against the closing price, adjusted for splits and bonuses. Each window uses
the same reference date as the table below, so the two agree. Funded value
moves with the price on its own, so the line under the chart reads the
share count instead — that is what shows whether more stock is
genuinely being borrowed against.
MTF book (₹ Cr)
Close price (₹)
Price and liquidity
Adjusted for splits and bonuses, so a change across a corporate action reflects the market rather than the share count.
Last close
₹826.95
as of 11 Sep 2026
Price, 30 days
+24.0%
adjusted for splits and bonuses
Delivery, 20-day avg
42.1%
of traded volume actually settled
Sessions to unwind
4.3
of average deliverable volume
Shares under margin divided by average daily deliverable volume over the last 20 sessions.
Book, shares and price by window
Funded value moves with the price on its own, so the share count is what shows whether more stock is actually being borrowed against. The last column reads the two together.
| Window | Book Δ | Book % | Shares | Price | Reading |
|---|---|---|---|---|---|
| 1 day | +₹1 | +1.6% | +1.5% +11,978 | −0.5% | building as it falls |
| 10 days | +₹4 | +7.1% | +5.9% +43,681 | +1.5% | building into strength |
| 30 days | +₹21 | +50.6% | +32.7% +1,94,485 | +22.5% | building into strength |
| 90 days | +₹21 | +48.1% | +32.6% +1,93,807 | +28.8% | building into strength |
| 180 days | +₹27 | +72.2% | +64.4% +3,08,883 | +17.9% | building into strength |
| 1 year | not enough history | ||||
Price is as of 11 Sep 2026; the MTF book is as of 10 Sep 2026. Exchanges publish the margin file a day after the market data, and the comparison above uses the MTF date for both sides.
Shares under margin
Number of shares funded via MTF over time (NSE + BSE combined).
Rank trajectory
Where AARTIPHARM has sat in the funded-value ranking each day
(1 = most funded). Lower is more prominent.
AARTIPHARM — last 30 trading days
Combined NSE + BSE funded value, day-on-day change, share of the whole book, and rank. Newest first.
| Date | Combined (₹ Cr) | Day Δ (₹ Cr) | % of book | Rank |
|---|---|---|---|---|
| 10 Sep 2026 | 64 | +₹1 | 0.04% | 557 |
| 09 Sep 2026 | 63 | +₹1 | 0.04% | 563 |
| 08 Sep 2026 | 61 | +₹0 | 0.04% | 568 |
| 07 Sep 2026 | 61 | +₹1 | 0.04% | 570 |
| 04 Sep 2026 | 60 | −₹0 | 0.04% | 581 |
| 03 Sep 2026 | 60 | −₹1 | 0.04% | 572 |
| 02 Sep 2026 | 61 | −₹1 | 0.04% | 564 |
| 01 Sep 2026 | 62 | +₹2 | 0.04% | 561 |
| 31 Aug 2026 | 60 | +₹0 | 0.04% | 569 |
| 28 Aug 2026 | 60 | +₹0 | 0.04% | 570 |
| 27 Aug 2026 | 60 | +₹2 | 0.04% | 575 |
| 26 Aug 2026 | 58 | +₹1 | 0.04% | 584 |
| 25 Aug 2026 | 56 | +₹2 | 0.04% | 589 |
| 24 Aug 2026 | 55 | +₹13 | 0.04% | 603 |
| 21 Aug 2026 | 42 | −₹2 | 0.03% | 713 |
| 20 Aug 2026 | 44 | −₹1 | 0.03% | 698 |
| 19 Aug 2026 | 44 | +₹0 | 0.03% | 693 |
| 18 Aug 2026 | 44 | +₹1 | 0.03% | 695 |
| 17 Aug 2026 | 43 | +₹2 | 0.03% | 705 |
| 14 Aug 2026 | 40 | −₹1 | 0.03% | 720 |
| 13 Aug 2026 | 42 | −₹0 | 0.03% | 714 |
| 12 Aug 2026 | 42 | −₹6 | 0.03% | 706 |
| 11 Aug 2026 | 48 | +₹14 | 0.03% | 655 |
| 10 Aug 2026 | 33 | −₹11 | 0.02% | 799 |
| 07 Aug 2026 | 44 | +₹0 | 0.03% | 683 |
| 06 Aug 2026 | 44 | +₹0 | 0.03% | 681 |
| 05 Aug 2026 | 43 | +₹1 | 0.03% | 685 |
| 04 Aug 2026 | 42 | −₹1 | 0.03% | 693 |
| 03 Aug 2026 | 43 | +₹0 | 0.03% | 690 |
| 31 Jul 2026 | 43 | — | 0.03% | 693 |
AARTIPHARM within Health Technology
Ranked #29 of 61 funded Health Technology stocks, carrying 1.0% of that sector’s margin book. Nearest names by funded value:
| # | Stock | MTF book (₹ Cr) | % of sector |
|---|---|---|---|
| 27 | SUVEN Suven Life Sciences Limited | ₹65 | 1.0% |
| 28 | ABBOTINDIA Abbott India Limited | ₹65 | 1.0% |
| 29 | AARTIPHARM Aarti Pharmalabs Limited | ₹64 | 1.0% |
| 30 | CAPLIPOINT Caplin Point Laboratories Limited | ₹61 | 1.0% |
| 31 | ZYDUSLIFE Zydus Lifesciences Limited | ₹58 | 0.9% |
Disclaimer. Data sourced from daily margin trading disclosure provided by NSE and BSE. This website and page are meant for educational and information only — not investment advice. MTF is leveraged and can amplify losses. Rules, margins, rates and eligible-stock lists change; verify current details with your broker and SEBI/exchange circulars. IndiaMTF.com is not a SEBI-registered intermediary, broker, or investment adviser and has no affiliation with SEBI, NSE or BSE. Figures are reproduced from publicly disclosed exchange data, may be delayed or revised, and should be independently verified before any trading decision. Consult a SEBI-registered investment adviser before investing.